157 related articles for article (PubMed ID: 36451831)
1. Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
Qiu J; Luo S; Yin W; Guo K; Xiang Y; Li X; Liu Z; Zhou Z
Front Immunol; 2022; 13():968798. PubMed ID: 36451831
[TBL] [Abstract][Full Text] [Related]
2. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
Liu YC; Liu H; Zhao SL; Chen K; Jin P
Front Immunol; 2023; 14():1164120. PubMed ID: 37359544
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J; Luo S; Yin W; Li X; Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):49-58. PubMed ID: 36935177
[TBL] [Abstract][Full Text] [Related]
4. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
5. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Kyriacou A; Melson E; Chen W; Kempegowda P
Clin Med (Lond); 2020 Jul; 20(4):417-423. PubMed ID: 32675150
[TBL] [Abstract][Full Text] [Related]
6. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
Hatayama S; Kodama S; Kawana Y; Otake S; Sato D; Horiuchi T; Takahashi K; Kaneko K; Imai J; Katagiri H
J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
[TBL] [Abstract][Full Text] [Related]
7. Type 1 diabetes related to immune checkpoint inhibitors.
Tachibana M; Imagawa A
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101657. PubMed ID: 35450793
[TBL] [Abstract][Full Text] [Related]
8. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
Basak EA; de Joode K; Uyl TJJ; van der Wal R; Schreurs MWJ; van den Berg SAA; Oomen-de Hoop E; van der Leest CH; Chaker L; Feelders RA; van der Veldt AAM; Joosse A; Koolen SLW; Aerts JGJV; Mathijssen RHJ; Bins S
Biomed Pharmacother; 2022 Dec; 156():113839. PubMed ID: 36228374
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
10. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study.
Bastin M; Allouchery M; Sassier M; Rouby F; Eftekhari P; Lebrun-Vignes B; Andreelli F; Bihan K
Therapie; 2021; 76(6):695-703. PubMed ID: 33836905
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
Wu L; Carlino MS; Brown DA; Long GV; Clifton-Bligh R; Mellor R; Moore K; Sasson SC; Menzies AM; Tsang V; Gunton JE
J Clin Endocrinol Metab; 2024 Apr; 109(5):1301-1307. PubMed ID: 37997380
[TBL] [Abstract][Full Text] [Related]
14. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
15. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
16. Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.
Labadzhyan A; Wentzel K; Hamid O; Chow K; Kim S; Piro L; Melmed S
J Clin Endocrinol Metab; 2022 Jun; 107(7):1976-1982. PubMed ID: 35303106
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA; Stanzer S; Spiegelberg J; Bauernhofer T; Absenger G; Posch F; Lipp R; Halm M; Szkandera J; Balic M; Gerger A; Smolle MA; Hutterer GC; Klec C; Jost PJ; Kargl J; Stradner M; Pichler M
Cancer Med; 2022 Aug; 11(16):3074-3083. PubMed ID: 35297215
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and immunological characteristics in rapid-onset type 1 diabetes with hyperamylasemia].
Zhang C; Zhou ZG; Zhang DM; Yang XL; Zhou M; Lin J; Huang G; Wang JP
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):967-71. PubMed ID: 16061004
[TBL] [Abstract][Full Text] [Related]
19. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.
Wright JJ; Johnson DB
J Clin Endocrinol Metab; 2023 May; 108(6):1514-1525. PubMed ID: 36481794
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database.
Lee M; Jeong K; Park YR; Rhee Y
Metabolism; 2023 Jan; 138():155311. PubMed ID: 36122764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
